Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 126 clinical trials
Simplifying Treatment and Monitoring for HIV (STREAM HIV)

This study seeks to determine the clinical efficacy and cost effectiveness of implementing an integrated model for HIV monitoring using point of care (POC) tenofovir (TFV) adherence testing and

  • 0 views
  • 16 Feb, 2021
  • 1 location
Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF

In Chronic hepatitis B (CHB) patients receiving long-term sequential Neucleos(t)ides(NAs), majority of these CHB patients experienced drug resistance and switched to Tenofovir disoproxil

antiviral drugs
hepatitis
fumarate
chronic hepatitis
tenofovir
  • 45 views
  • 25 Jan, 2021
  • 1 location
Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

This study will evaluate the safety and efficacy of the long-acting injectable agent cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre

local anesthetic
emtricitabine
hepatitis
hiv test
immune globulin
  • 767 views
  • 25 Jan, 2021
  • 22 locations
Pharmacokinetic Safety and Efficacy of B/F/TAF in HIV-1 Infected Virologically Suppressed Pregnant Women in Their Second and Third Trimesters

The primary objective of this study is to evaluate the steady state pharmacokinetics of bictegravir (BIC) and confirm the dose of BIC/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg

  • 60 views
  • 13 Feb, 2021
  • 19 locations
A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B

The aim of the prospective real-world study is to evaluate whether sequential combination therapy with pegylated interferon plus entecavir/tenofovir could induce higher rates of HBsAg loss in

entecavir
hepatitis b antigen
chronic hepatitis
tenofovir
interferon
  • 41 views
  • 22 Jan, 2021
  • 10 locations
Evaluating the Pharmacokinetics Feasibility Acceptability and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum

The purpose of this study is to evaluate the pharmacokinetics, feasibility, acceptability, and safety of a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as

emtricitabine
hepatitis
drug levels
emtricitabine/ tenofovir disoproxil fumarate
tenofovir
  • 48 views
  • 24 Jan, 2021
  • 6 locations
Study Evaluating Pharmacokinetics (PK) Safety and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Virologically Suppressed Pediatric Participants

to < 12 years of age) To evaluate the steady-state PK of tenofovir alafenamide (TAF) and confirm the dose of emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected pediatric

tuberculosis
emtricitabine/tenofovir
cobicistat
tenofovir
antiretroviral agents
  • 236 views
  • 28 Jan, 2021
  • 37 locations
Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines

Treatment with Tenofovir Alafenamide(TAF) in Chronic Hepatitis B (CHB) patients classified as beyond treatment indication of current international guidelines (e.g. aged more than 40 years old

estimated creatinine clearance
hepatitis
hepatitis b antigen
hepatitis b e antigen
chronic hepatitis
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Study to Evaluate the Pharmacokinetics Safety Tolerability and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

investigator-selected background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs) (zidovudine [AZT], abacavir [ABC], or tenofovir disoproxil fumarate [TDF] in combination

  • 169 views
  • 28 Jan, 2021
  • 25 locations
Randomized Double-blind Efficacy and Safety Study of Doravirine/Islatravir (DOR/ISL) in Treatment-na ve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

treatment-nave participants with human immunodeficiency virus type-1 (HIV-1) infection. The primary hypothesis is that DOR/ISL is non-inferior to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF

  • 4 views
  • 03 Mar, 2021
  • 35 locations